We issued a new guideline on Symptom Management for Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors.
Read full article: brnw.ch/21wSxLk
#GEPNets
Read full article: brnw.ch/21wSxLk
#GEPNets
May 9, 2025 at 10:24 PM
We issued a new guideline on Symptom Management for Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors.
Read full article: brnw.ch/21wSxLk
#GEPNets
Read full article: brnw.ch/21wSxLk
#GEPNets
🔬 Join #ASOChat: Exploring breakthrough NET research!
Dr. Howe & Dr. Halfdanarson discuss "PRRT Improves Survival in Patients Who Progress After Resection of GEPNETs" - new findings in #JournalASO
📅 Jan 30, 6-7PM EST
📍 Live on X & BlueSky
#NETs #SurgOnc #MedTwitter
Dr. Howe & Dr. Halfdanarson discuss "PRRT Improves Survival in Patients Who Progress After Resection of GEPNETs" - new findings in #JournalASO
📅 Jan 30, 6-7PM EST
📍 Live on X & BlueSky
#NETs #SurgOnc #MedTwitter
January 24, 2025 at 9:15 PM
🔬 Join #ASOChat: Exploring breakthrough NET research!
Dr. Howe & Dr. Halfdanarson discuss "PRRT Improves Survival in Patients Who Progress After Resection of GEPNETs" - new findings in #JournalASO
📅 Jan 30, 6-7PM EST
📍 Live on X & BlueSky
#NETs #SurgOnc #MedTwitter
Dr. Howe & Dr. Halfdanarson discuss "PRRT Improves Survival in Patients Who Progress After Resection of GEPNETs" - new findings in #JournalASO
📅 Jan 30, 6-7PM EST
📍 Live on X & BlueSky
#NETs #SurgOnc #MedTwitter
#GEPNETs are among most common NETs but easily misdiagnosed with many gastric conditions.
📌Katja from the Netherlands spent 6 years with gastric symptoms. Finally, a scan revealed the tumors in the stomach and bowels.
📱Watch her story: incalliance.org/stories/katj...
#LetsTalkAboutNETs
📌Katja from the Netherlands spent 6 years with gastric symptoms. Finally, a scan revealed the tumors in the stomach and bowels.
📱Watch her story: incalliance.org/stories/katj...
#LetsTalkAboutNETs
August 6, 2025 at 6:16 AM
#GEPNETs are among most common NETs but easily misdiagnosed with many gastric conditions.
📌Katja from the Netherlands spent 6 years with gastric symptoms. Finally, a scan revealed the tumors in the stomach and bowels.
📱Watch her story: incalliance.org/stories/katj...
#LetsTalkAboutNETs
📌Katja from the Netherlands spent 6 years with gastric symptoms. Finally, a scan revealed the tumors in the stomach and bowels.
📱Watch her story: incalliance.org/stories/katj...
#LetsTalkAboutNETs
DLL3 expression in high-grade NENs? Not rare at all! Check out this large study. 64% of NECs pos, 42% lung NETs, but only 5% GEPNETs are pos with the exception of G3 NETs which are 20% mod or strongly pos. DLL3-directed trials coming but not for G3 NETs.
link.springer.com/article/10.1...
link.springer.com/article/10.1...
DLL3 Expression in Neuroendocrine Carcinomas and Neuroendocrine Tumours: Insights From a Multicentric Cohort of 1294 Pulmonary and Extrapulmonary Neuroendocrine Neoplasms - Endocrine Pathology
Delta-like ligand 3 (DLL3) is frequently expressed in pulmonary small cell neuroendocrine carcinoma (SCNEC) and has emerged as a promising therapeutic target. However, limited data on DLL3 expression ...
link.springer.com
March 30, 2025 at 3:45 PM
DLL3 expression in high-grade NENs? Not rare at all! Check out this large study. 64% of NECs pos, 42% lung NETs, but only 5% GEPNETs are pos with the exception of G3 NETs which are 20% mod or strongly pos. DLL3-directed trials coming but not for G3 NETs.
link.springer.com/article/10.1...
link.springer.com/article/10.1...
Does radiosensitizing capecitabine improve the efficacy of PRRT in progressive GEPNETs...? This small phase II RCT does not suggest so and I remain thoroughly unconvinced that adding chemo to PRRT does anything beneficial. Big kudos to this team!
jnm.snmjournals.org/content/earl...
jnm.snmjournals.org/content/earl...
177Lu-DOTATATE Plus Capecitabine Versus 177Lu-DOTATATE Alone in Patients with Advanced Grade 1/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial
177Lu-DOTATATE has emerged as a viable treatment strategy for advanced well-differentiated grade 1/2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Few retrospective studies have shown conco...
jnm.snmjournals.org
January 10, 2025 at 1:54 PM
Does radiosensitizing capecitabine improve the efficacy of PRRT in progressive GEPNETs...? This small phase II RCT does not suggest so and I remain thoroughly unconvinced that adding chemo to PRRT does anything beneficial. Big kudos to this team!
jnm.snmjournals.org/content/earl...
jnm.snmjournals.org/content/earl...
Now on demand ▶️
Gain practical insights for NET management.
Sessions available:
🔹 Early NET Treatment Decisions: Recognizing When to Initiate and Escalate Therapy
🔹 Advanced GEP-NET Management: Personalizing Systemic and Targeted Therapy
Watch now: bit.ly/4epl13N
#NETs #GEPNETs #Oncology
Gain practical insights for NET management.
Sessions available:
🔹 Early NET Treatment Decisions: Recognizing When to Initiate and Escalate Therapy
🔹 Advanced GEP-NET Management: Personalizing Systemic and Targeted Therapy
Watch now: bit.ly/4epl13N
#NETs #GEPNETs #Oncology
June 24, 2026 at 8:00 PM
Now on demand ▶️
Gain practical insights for NET management.
Sessions available:
🔹 Early NET Treatment Decisions: Recognizing When to Initiate and Escalate Therapy
🔹 Advanced GEP-NET Management: Personalizing Systemic and Targeted Therapy
Watch now: bit.ly/4epl13N
#NETs #GEPNETs #Oncology
Gain practical insights for NET management.
Sessions available:
🔹 Early NET Treatment Decisions: Recognizing When to Initiate and Escalate Therapy
🔹 Advanced GEP-NET Management: Personalizing Systemic and Targeted Therapy
Watch now: bit.ly/4epl13N
#NETs #GEPNETs #Oncology
Phase 3 Clinical Trial of PRRT ITM11 177Lu-Edotreotide - COMPETE for GEPNETs
Phase 3 Clinical Trial of PRRT ITM11 177Lu-Edotreotide – COMPETE for GEPNETs
Update - 9th October 2025. ITM Presents Dosimetry Data from Phase 3 COMPETE Trial Supporting Favorable Efficacy and Safety Profile with n.c.a. 177Lu-edotreotide (ITM-11) in Patients with Gastroenteropancreatic Neuroendocrine Tumors at EANM 2025 Annual Congress Barcelona, Spain, October 8, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced dosimetry data from its Phase 3 COMPETE trial in patients with Grade 1 or Grade 2 somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with n.c.a.
ronnyallan.net
October 9, 2025 at 3:01 PM
Phase 3 Clinical Trial of PRRT ITM11 177Lu-Edotreotide - COMPETE for GEPNETs
Phase 3 Clinical Trial of PRRT ITM11 177Lu-Edotreotide - COMPETE for GEPNETs
Phase 3 Clinical Trial of PRRT ITM11 177Lu-Edotreotide – COMPETE for GEPNETs
Update - 28th January 2025. ITM Announces Positive Topline Results of Phase 3 COMPETE Trial with ITM-11, a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Garching / Munich, January 28, 2025 - ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced positive topline results from its Phase 3 COMPETE trial in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
ronnyallan.net
January 29, 2025 at 4:04 PM
Phase 3 Clinical Trial of PRRT ITM11 177Lu-Edotreotide - COMPETE for GEPNETs